Thermal Necrosis Thresholds in Human Nasal Tissues: A Comparative Analysis of Normal, Inflammatory, and Neoplastic Pathologies Under Controlled Energy Exposure

Background: Thermal energy-based interventions are widely used in otolaryngology for the treatment of nasal pathologies including polyps, chronic inflammation, and tumors. However, tissue-specific thermal thresholds for necrosis remain poorly characterized, leading to variability in clinical outcomes and risk of collateral damage. Objective: To determine and compare the thermal necrosis thresholds—defined by temperature, duration, and energy modality—across normal nasal mucosa, nasal polyps, inflamed tissue, benign tumors, and malignant tumors. Methods: Ex vivo human nasal tissues (n = 150) were exposed to controlled thermal energy via radiofrequency ablation (RFA), laser (CO₂/diode), electrocautery, and cryotherapy. Temperature was monitored with real-time thermocouples; duration varied from 1–20 seconds. Histopathological analysis (H&E staining) assessed necrosis, while biochemical markers (caspase-3 activity, LDH release) quantified cellular injury. Thresholds were defined as the minimum temperature-duration combination yielding >90% coagulative necrosis. Results: Nasal polyps and inflamed tissues demonstrated the lowest necrosis thresholds (55–60°C, 3–8 s), attributed to high vascularity and water content. Normal mucosa required significantly higher temperatures (70–80°C, 10–20 s). Benign tumors (papillomas, hemangiomas) exhibited intermediate sensitivity (60–70°C, 5–15 s). Malignant tissues (squamous cell carcinoma, adenocarcinoma) showed marked heterogeneity: SCC required 65–80°C (5–20 s), while adenocarcinoma responded at lower temperatures (50–70°C, 5–20 s), likely due to variable vascularization. Cryotherapy induced delayed necrosis after 1–2 min at <−20°C. RFA at 5–10 W (60–65°C, 5–10 s) achieved optimal efficacy with minimal collateral damage in polyps. Conclusion: Thermal necrosis thresholds vary significantly across nasal tissue types. Tailoring energy parameters to histopathology—rather than applying standardized protocols—can enhance therapeutic precision, minimize complications, and ...